Adjuvants in Allergy
The Annual Scientific meeting of Allergy Therapeutics
2nd - 4th July 2015, Amsterdam
Global patterns of Allergens, Climate Change and Impact of Migration

**Chairs:** Prof Triggiani (Salerno), Prof Matthias Kramer (ATL)
**Speakers:** Prof Uwe Berger, Prof Karl Christian Bergmann, Prof Carlo Lombardi - Respiratory allergic diseases and immigrants, Dr. Dolores Hernandez

**Subject:** Significant changes to the climate and patterns of migration are presenting new therapeutic and diagnostic demands for the Allergist. These changes whilst global are particularly impacting on clinical care in Europe. The changes in climate, the patterns of migration and how this has impacted on allergists will be covered. The distribution of pollen counts and their annual patterns together with services that provide personalise predictions for patients will be covered.

Tea 4pm

4.30pm

Genetics and Epigenetics “Nature or Nurture” in Allergy

**Chairs:** Prof Ignacio Jesús Dávila González, Dr Fillipo Fassio
**Speakers:** Prof Dr Michael Kabesch, Prof Dr Harald Renz

**Subject:** The future therapy of allergic disease will be discovered through the new scientific knowledge of how environmental factors can precipitate disease in people with heritable susceptibilities. This knowledge will also enhance diagnostic accuracy by the recognition of environmental risk factors. Both the science and the clinical relevance will be explored.

Finish 5.30pm

ATL lecture 6pm

Does an increase in the cumulative allergen dose increase the clinical efficacy of vaccines?

**Chair:** Prof Ludger Klimek
**Speaker:** Prof Pascal Demoly

**Subject:** The Allergy Therapy Ordinance (TAV) of the Paul Erhlich Institute, which requires for Market Authorization of named patient prescribed vaccines a dose selection study, has stimulated a great interest in the relationship between cumulative dose of allergen (Allergoid) and efficacy. This dose selection study is to determine the best dose to take forward in the phase III study.

Before 2012 for SCIT there had been only one double blind randomised dose ranging study. Since the introduction of the TAV the number of studies has dramatically increased. Not all have been successful. This lecture will consider the relationship between cumulative allergen dose and the change in measurements of symptoms.

Dinner 7pm
9am

**Immunological changes with clinically successful therapy?**

**Chairs:** Prof Tim Higenbottam, Dr Enrico Heffler  
**Speakers:** Prof Stephen Durham, Prof Dario Antolin-Amerigo - Alterations in T lymphocyte function in allergic rhinitis, Prof Enrico Maggi, Dr Daphne Tsitoura – The immunological changes associated with adjuvants

**Subject:** The generation and maintenance of allergen-specific T-cell tolerance is a key step in healthy immune responses to allergens. The latest reports on therapy induced changes to the innate immune system will be discussed with relevance determining efficacy and duration of different therapy. The opportunity to achieve sustained disease modification will be explored. The importance in clinical practice of this research will be emphasised.

Coffee 11am

11.30am

**Adjuvants their role in new vaccines**

**Chairs:** Prof Gianenrico Senna, Dr Daphne Tsitoura  
**Speakers:** Univ. Prof. Dr. Erika Jensen-Jarolim, Prof Giovanni Rolla, Prof Dr Ludger Klimek, Prof Dr. Med Thomas Kuendig

**Subject:** A major development on disease modifying agents which aim to restore the type1 T helper cell balance rather than type 2 has provided insights to both the opportunities and weaknesses of using the innate immune mechanism on their own. New thinking on adjuvants to enhance the immune response to allergy vaccines will be explored.

Lunchtime 12.30pm

1.30pm

**Immunomodulatory Therapies and Probiotics**

**Chairs:** Prof Stefan Wöhrl, Dr Manuel Rial  
**Speakers:** Prof Dr Margitta Worm, Prof Dr Christian Poets, Prof Santiago Quirce, Prof Antonio Nieto

**Subject:** To explain the dramatic increase in the prevalence of allergic diseases, the hygiene hypothesis proposed that early exposure to infection prevented allergic diseases. The hygiene hypothesis has changed to the microbial hypothesis, in which exposure to microbes is closely linked to the development of the early immune system and allergic diseases. The intestinal flora may contribute to allergic disease through its substantial effect on mucosal immunity.

Based on findings that exposure to microbial flora early in life can change the Th1/Th2 balance, thus favouring a Th1 cell response, probiotics may be beneficial in preventing allergic diseases. Study limitations, have impeded the progress in this area in many allergic diseases, but many studies have demonstrated a significant clinical improvement in atopic dermatitis with the use of probiotics.

Tea 3.30pm
Second afternoon session 4pm

**Immunotherapy for Prevention of Allergy**

**Chairs:** Dr Albert Roger, Dr Marco Caminati  
**Speakers:** Prof Graham Roberts, Dr G Passalacqua, Prof Ulrich Wahn, Dra. Marta Reche Frutos  
**Subject:** The massive consequences of acquiring allergy disease on quality and duration of life has driven the question to understand how Allergy vaccines could potentially prevent the acquisition of the multiple expressions of allergy

Finish 5.30pm

**Posters and “Happy Hour”**

Dinner 8pm

4th July

9am

**Workshops and keynote lecture**

**Keynote speaker:** Professor Gideon Lack “Food Allergy”  
**Chair:** Prof Walter Canonica

10am

**Workshop 1: Setting up an allergy Clinic**

**Speakers:** Dr Giusi Manzotti, Dr Louise Michaelis, Dr Ana Cabal

Three leaders in allergy will discuss their successes but also the trials and tribulations in setting up allergy clinics

**Workshop 2: Aero allergen Challenge Testing**

**Speakers:** Prof Jens Hohlfeld - “Environmental challenge chamber - Efficacy testing and more”  
Prof Ludger Klimek - Nasal Challenge  
Prof Ralph Moeges - CPT

Three leaders in aero-allergen challenges will define the major contributors to success in diagnosis and therapy management

Finish 11.30am

**Awards to the Posters 11.30am**

End of meeting 12 midday
Scientific Advisory Board

Chair: Prof Walter Canonica  
Prof Ludger Klimek  
Prof Thomas Kuendig (Zurich)  
Dr Stefan Wöhrl (Vienna)  
Prof Graham Roberts (Southampton)  
Prof Ralph Moeges (Cologne)  
Dr Albert Roger (Barcelona)  
Dr Filippo Fassio (Pistoia)  
Dr Louise Michaelis (Newcastle)  
Prof Pascal Demoly (Montpellier)

ATL and Bencard Support Team

Murray Skinner  
Matthias Kramer  
Fabio Guagnini  
Santiago Puig  
Tim Higenbottam